Viking Therapeutics

Na chamada de resultados do Q3 2026, a Viking Therapeutics discutiu seu fármaco para obesidade VK2735, mostrando perda de peso de até 22% com esquemas de dosagem menos frequentes.

fool.com · 29 de out. de 2026, 04:13 UTC

Viking Therapeutics reported a third quarter 2026 net loss of $183.2 million and confirmed that enrollment is complete in its VK2735 injectable clinical trials.

tradingview.com · 30 de out. de 2026, 13:32 UTC